MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults

OBJECTIVE: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH deficiency (GHD). This study’s objec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Endocrinol
Main Authors: Strasburger, Christian J, Vanuga, Peter, Payer, Juraj, Pfeifer, Marija, Popovic, Vera, Bajnok, László, Góth, Miklós, Olšovská, Veˇra, Trejbalová, L‘udmila, Vadasz, Janos, Fima, Eyal, Koren, Ronit, Amitzi, Leanne, Bidlingmaier, Martin, Hershkovitz, Oren, Hart, Gili, Biller, Beverly M K
Formato: Artigo
Idioma:Inglês
Publicado em: Bioscientifica Ltd 2016
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5292974/
https://ncbi.nlm.nih.gov/pubmed/27932411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-16-0748
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados